FIELD: pharmaceuticals.
SUBSTANCE: invention relates to gastro-resistant dosage forms with controlled release containing Compound (I):
or a pharmaceutically acceptable salt and/or solvate thereof, the pharmacokinetic properties of these dosage forms and their preparation.
EFFECT: novel dosage forms disclosed herein are useful for reducing the risk of QT prolongation in a subject and for treating a disorder in a subject in need thereof, for example in a subject diagnosed with schizophrenia, for instance in treating negative symptoms in a subject diagnosed with schizophrenia having CYP2D6 EM genotype.
22 cl, 31 dwg, 53 tbl, 22 ex
